Menu

Recent Interviews

Ryan Jackson, CEO, Newlox Gold Ventures Corp.

Ryan Jackson
CEO | Newlox Gold Ventures Corp.
60 Laurie Crescent, V7S 1B7 West Vancouver (CAN)

info@newloxgold.com

+1 778 738 0546

Newlox CEO Ryan Jackson on building a green gold producer with a rapid growth trajectory


Nick Mather, CEO, SolGold PLC

Nick Mather
CEO | SolGold PLC
1 King Street, EC2V 8AU London (GB)

emichael@solgold.com.au

+44 20 3823 2125

SolGold CEO Nick Mather on building a major gold and copper mining company


Jared Scharf, CEO, Desert Gold Ventures Inc.

Jared Scharf
CEO | Desert Gold Ventures Inc.
4770 72nd St,, V4K 3N3 Delta (CAN)

jared.scharf@desertgold.ca

Desert Gold Ventures CEO Jared Scharf on West Africa and its potential


13. November 2020 | 12:48 CET

EXMceuticals, KWS Saat, Nokia: Talk about crashes and comebacks

  • Investments
Photo credits: pixabay.com

When the EXMceuticals share was quoted above the 1 EUR mark last summer, the sky hung full of violins for cannabis investors. In North America, the active ingredient was largely liberalized, and in other regions of the world, too, it seemed that cannabis would soon become a medical substance like many others. But at least the hype has died down on the stock market. In the meantime, EXMceuticals shares are trading at just EUR 0.12. What has happened?

time to read: 3 minutes by Nico Popp


 

Author

Nico Popp

At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

About the author


EXMceuticals: Cannabis Play is about to start in Europe

More than a year ago, the Company focused on the cultivation and production of cannabis in Africa. Now, EXMceuticals has set its sights on a regulated market and operates in Portugal. Here, the Company has a processing plant for the extraction of active ingredients from cannabis plants. The focus here is on medical applications. EXMceuticals is confident that future growth will not be in the area of pure raw materials but in processed products. However, to produce pastilles, creams or even cookies, it must be possible to supply them with the desired active ingredient in exact doses. This requires the prior processing of the raw material, cannabis.

In Germany, medical cannabis has been liberalized since 2017. Other European countries also tolerate private use as a luxury food. EXMceuticals considers itself well-positioned in case of further market liberalization in Europe and emphasizes its focus on the processing of cannabis. While pure cultivation is not a challenge, the extraction of the active ingredients is essential. Here the Company scores with a certified processing plant according to pharmacological standards.

Furthermore, the Company already has agreements with European companies to be able to start the activities quickly. Currently, EXMceuticals is waiting for credit approval from Portuguese banks to be able to advance the business further. Other Portuguese investors have already shown interest. The share currently seems to be at rock bottom, but further liberalization trends within the less competitive European cannabis market, as well as additional financing commitments, could revive the speculative value.

After a rollercoaster ride Profiteer of climate change: KWS Saat

KWS Saat is a stock that has also seen ups and downs. More than ten years ago, when demography and the rise of more inferior population groups in emerging markets was an investment topic, many investors rushed to fertilizer and seed manufacturers. A veritable hype arose. During the financial crisis, many expectations came back, down to earth. But KWS Saat shares fought their way back up again. Today, the Company is mainly active in Europe and the USA and makes money with both cereals and vegetables. A new megatrend is also attracting shareholders: Climate change is changing cultivation conditions in many regions and even leading to failed harvests. With the help of specialized seeds, farmers can meet these challenges.

Looking ahead to the current fiscal year, the Company expects growth of between 8% and 12%. The margin should also be very respectable at 11% to 13%. With this positioning, the Company is in demand on the stock market. Although a return of only 5.8% can be achieved on a one-year horizon, the share took off in the first half of the year and made a return of more than 50% within a few weeks. The dividend also shows that the value is a solid investment, with the dividend yield at around 1%.

Nokia: With luck, the 5G hype is entirely on target

Nokia also shows that a crash on the stock market does not have to be the end. For more than a decade, the Finnish Company was the best-known cell phone manufacturer in the world. But then came the iPhone and then the Android smartphones. The Finns missed this train, and the stock even staggered into the range around one Euro. But with the sale of the cell phone division, the Company succeeded in making a liberating move. Nokia is now a network supplier. Although there are always critical voices because the competition from China is cheaper, trade wars and protectionism could lead to Chinese manufacturers being left out in Europe and the USA in connection with 5G technology, as has already happened in some cases. The Company has achieved a turnaround and even boasts a good equity ratio. With a bit of luck, the 5G boom will have a full impact on Nokia's business.

Fallen angels offer chances

The history of the stock market is full of setbacks of former favourites and subsequent recoveries. Sometimes it even takes a while until the market rediscovers these fallen angels. For shareholders who look closely, this can be an opportunity. But sometimes, as a shareholder, you also need patience. Shares that have already been through a hype often find it incredibly challenging to get back on the market.


Author

Nico Popp

At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

27. November 2020 | 09:19 CET | by Stefan Feulner

BYD, Canadian Solar, Silver Viper - don't miss the start!

  • Investments

The optimism for life in normality is growing more and more with the successful test results concerning the vaccines against the coronavirus. The administration of a vaccine, which is to be available to the general public from spring 2021 onwards, should make it possible to relax increasingly in everyday life. If one reads the daily news, the pandemic seems to be contained and thus controllable within a few months. The "victims" of this development are the crisis currencies gold and silver. After their highs, both precious metals and mining stocks are initially taking a breather - but a comeback is very likely.

Read

25. November 2020 | 11:44 CET | by Nico Popp

Sartorius, Drägerwerk, Desert Gold: Vaccines for the portfolio

  • Investments

The crisis is on the home stretch. Several vaccines have been found and are about to be approved. But it will still take a while before the pandemic is defeated: millions of people need to be vaccinated. Usually, two doses of vaccine are required for this purpose, which must be administered at specific intervals. This Herculean logistical task must succeed in many countries if normality is to be restored. This much seems inevitable: 2021 will still be under the influence of the virus. Corona also leaves its mark on the capital market, whether directly or indirectly.

Read

25. November 2020 | 11:15 CET | by Stefan Feulner

Moderna, Triumph Gold, BioNTech - bet on winners!

  • Investments

Gold has not made it out - for the time being. Due to the decision of the Americans pro Joe Biden and the very successful developments regarding a vaccine against the coronavirus, the precious yellow metal went downhill for the time being. The correction may well continue a little further. However, in the past, these setbacks were lucrative with anti-cyclical entry opportunities. Therefore, one should use the time now to take a closer look at promising gold mines.

Read